Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arcus Biosciences (RCUS)

Arcus Biosciences COO Jennifer Jarrett to resign effective March 30, 2026

Neutral Impact 3 of 5 leadership Written later

Arcus Biosciences said Chief Operating Officer Jennifer Jarrett decided to resign, effective March 30, 2026, and that the resignation is not due to any disagreement with the company on operations, policies or practices. Under a separation agreement, she will provide periodic advisory services through June 30, 2026, and the company extended her post-termination option exercise period to twelve months.

Key points

  • Jennifer Jarrett resigns as Chief Operating Officer, effective March 30, 2026; notice given March 17, 2026
  • Resignation is stated to be unrelated to any disagreement with the company
  • Jarrett will provide advisory services through June 30, 2026; vested options exercisable for twelve months after termination
  • Full separation agreement to be filed with the next Form 10-Q

The filing

CompanyArcus Biosciences (RCUS)
Form8-K, current report
Filed with the SECMar 23, 2026, 7:46 AM ET
Accession number0001724521-26-000014

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.